CHMP Issues a Positive Opinion on Janssen’s Single-Agent DARZALEX® (daratumumab)
Go back to CHMP Issues a Positive Opinion on Janssen’s Single-Agent DARZALEX® (daratumumab)| Johnson & Johnson (NYSE: JNJ) | Delayed: 267.13 -4.82 (1.77%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $271.95 | 52 Week High | $126.07 | |||
| Open | $269.11 | 52 Week Low | $94.28 | |||
| Day High | $271.89 | P/E | 55.54 | |||
| Day Low | $265.59 | EPS | $4.81 | |||
| Volume | 1,326,537 | |||||
